Multimodal treatment of glomus jugular tumours
| Autor: | F. Stoica, G. Popescu, Francesca Paslaru, Anamaria Gheorghiu, A.C. Paslaru, M. Apostol, M.C. Zaharia, R. M. Gorgan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Romanian Neurosurgery, Vol 36, Iss 2 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1220-8841 2344-4959 |
| Popis: | Glomus jugulare tumours are extremely rare, slow-growing, hypervascular tumours that arise within the jugular foramen of the temporal bone and frequently involve the lower cranial nerves. We performed a retrospective study for patients treated between January 2005 and December 2019, reviewing clinical and radiological data for 91 cases of glomus jugulare tumours. Data were available for 91 patients presenting with 96 tumours. Surgery was 1st intention of treatment for 13 cases, the endovascular approach was 1st intention for 6 cases and GKRS was primarily performed in 72 cases. Combined treatment options were used in 19 cases. The median age at the time of treatment was of 57 years. The tumour volume varied between 0.5 and 73.4 cm3 with a median value of 8.3 cm3. For the cases treated with GKRS, the peripheral dose ranged between 8 and 35 Gy on the 35% to 65% isodose, with a median of 14 Gy on the 45% isodose. The average follow-up was 38 months with a maximum of 94 and consisted of contrast-enhanced MRI every six months in the first year after the procedure and every 1 to 2 years afterwards. The overall tumour control rate was 95.6% using multimodal treatment options for glomus jugulare tumours. Multimodal treatment for glomus jugulare tumours offers the patient the chance for the best possible outcome and long-term survivability. An individual treatment approach for this kind of very rare head and neck tumour (0,6% of all head and neck tumours) is recommended to choose the best risk-versus-benefit treatment option. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|